 |
Minimalna wpłata $50 Ekskluzywna promocja |
Nasz wynik |
0% prowizja |
Are you looking to buy Sarepta Therapeutics stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:SRPT! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Sarepta Therapeutics stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense’s lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Średnia wielkość
3.65 million shs
KAPITAŁ RYNKOWY
$7.50 billion
Giełda Papierów Wartościowych
NASDAQ
Proszę kupić te akcje!
|
NAZWA
|
TICKER
|
PRZEMYSŁ
|
SEKTOR
|
VOLUME
|
KUP TERAZ TĘ AKCJĘ
|
|---|---|---|---|---|---|
|
NASDAQ:SRPT
|
Preparaty farmaceutyczne
|
Medyczny
|
18,961 shs
|
Below is a quick guide on how to buy NASDAQ:SRPT stocks safe, fast and around the world in less than five minutes.
Krok 1: Otworzyć rachunek w eToro – eToro is the best broker to buy Sarepta Therapeutics shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Krok 2: Załadować Państwa ID - Zgodnie z przepisami KYC eToro poprosi Państwa o przesłanie kopii paszportu lub prawa jazdy.
Krok 3: Wpłata środków - Proszę wpłacić trochę pieniędzy na swoje nowo utworzone konto eToro. Mogą Państwo wybrać pomiędzy przelewem bankowym, e-wallet lub kartą debetową/kredytową lub Paypal.
Krok 4: Buy Sarepta Therapeutics – Search for “”NASDAQ:SRPT”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Sarepta Therapeutics stocks with 0% commission!.
1 | | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
24 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Sarepta Therapeutics in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Sarepta Therapeutics stock.
Wall Street analysts have given Sarepta Therapeutics a “Buy” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Sarepta Therapeutics wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
2 |  | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
3 |  | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:SRPT stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Sarepta Therapeutics stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Sarepta Therapeutics stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Ponieważ eToro jest platformą regulowaną, musi Pan wypełnić proces KYC, jest to standardowa procedura i zajmuje tylko kilka minut. Musi Pan przedstawić dowód tożsamości ze zdjęciem (paszport, prawo jazdy) oraz dowód adresu (rachunek za media, wyciąg z banku).
Po zarejestrowaniu się i zweryfikowaniu konta, należy wpłacić środki. eToro akceptuje karty kredytowe/debetowe, przelewy bankowe, a także e-wallety. Tak więc niezależnie od Państwa preferencji znajdzie się coś dla Państwa.
Now that you’ve funded your eToro account, just type “NASDAQ:SRPT stocks" w pasku wyszukiwania na górze ekranu i nacisnąć "handel".
All that’s left is to buy some NASDAQ:SRPT stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:SRPT is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Sarepta Therapeutics stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Sarepta Therapeutics.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its earnings results on Thursday, November, 5th. The biotechnology company reported ($2.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.89) by $0.61. The biotechnology company earned $143.92 million during the quarter, compared to analyst estimates of $133.69 million. Sarepta Therapeutics had a negative net margin of 121.30% and a negative trailing twelve-month return on equity of 61.62%. The business’s revenue for the quarter was up 45.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.14) earnings per share.
View Sarepta Therapeutics’ earnings history.
Sarepta Therapeutics’ stock was trading at $102.8150 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SRPT shares have decreased by 6.9% and is now trading at $95.73.
24 analysts have issued twelve-month price objectives for Sarepta Therapeutics’ shares. Their forecasts range from $73.00 to $240.00. On average, they anticipate Sarepta Therapeutics’ share price to reach $161.96 in the next year. This suggests a possible upside of 69.2% from the stock’s current price.
View analysts’ price targets for Sarepta Therapeutics or view top-rated stocks among Wall Street analysts.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:SRPT stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Ponad 95% środków klientów jest przechowywanych w trybie offline, w zimnym magazynie, co jest kluczowe dla każdego brokera, który zarządza Państwa aktywami. Niezależnie od tego, jak bezpieczna ma być platforma, zalecamy stosowanie 2FA, aby dodać dodatkową warstwę bezpieczeństwa do Państwa konta.
eToro oferuje użytkownikom szereg funkcji, aby mogli Państwo jak najszybciej zacząć inwestować. Mają Państwo stosunkowo unikalną funkcję copy trading, która pozwala na uzyskanie pasywnego dochodu poprzez odzwierciedlanie doświadczonych traderów, co pozwala szybko zacząć zarabiać i daje lepsze zrozumienie strategii stosowanych przez profesjonalistów. Dodatkowo eToro umożliwia użytkownikom inwestowanie w zarządzane portfele, przy czym zarządzany portfel to różne podobne aktywa zgrupowane razem, co pozwala na dywersyfikację konta i zmniejsza ewentualne ryzyko. Dla tych, którzy mają już doświadczenie w handlu, mogą Państwo inwestować na rynkach poza akcjami, ponieważ eToro pozwala użytkownikom na handel ETF-ami, towarami, kryptowalutami i indeksami. Jeżeli już inwestują Państwo poza przestrzenią giełdową, może to być bardzo przydatne, ponieważ pozwala to na zarządzanie wszystkimi Państwa inwestycjami w jednym miejscu.
Sarepta Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 8,100,000 shares, an increase of 14.6% from the December 31st total of 7,070,000 shares. Based on an average trading volume of 1,780,000 shares, the days-to-cover ratio is presently 4.6 days.
View Sarepta Therapeutics’ Short Interest.
Sarepta Therapeutics’ management team includes the following people:
Mr. Douglas S. Ingram, Pres, CEO & Director (Age 58, Pay $1.39M)
Mr. William F. Ciambrone, Exec. VP of Technical Operations (Age 57, Pay $438.01k)
Mr. David Tyronne Howton Jr., Consultant (Age 49, Pay $731.8k)
Dr. Gilmore O’Neill M.D., Exec. VP of R&D and Chief Medical Officer (Age 56, Pay $933.33k)
Mr. Ian Michael Estepan, Exec. VP, Principal Financial and Accounting Officer & CFO (Age 45)
Dr. Louise Rodino-Klapac Ph.D., Exec. VP & Chief Scientific Officer
Mr. Ryan E. Brown, VP, Global Chief Compliance Officer, Regulatory Counsel & Interim Gen. Counsel
Dr. Diane L. Berry, Sr. VP of Global Health Policy and Gov. & Patient Affairs
Ms. Joan Nickerson M.B.A., Sr. VP of HR
Mr. Dallan Murray, Sr. VP & Chief Commercial Officer
CFD są złożonymi instrumentami i wiążą się z wysokim ryzykiem szybkiej utraty pieniędzy z powodu dźwigni finansowej. 68% kont inwestorów detalicznych traci pieniądze przy handlu CFD u tego dostawcy. Powinni Państwo rozważyć, czy rozumieją Państwo, jak działają kontrakty CFD i czy mogą sobie Państwo pozwolić na wysokie ryzyko utraty pieniędzy.
15 employees have rated Sarepta Therapeutics CEO Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among Sarepta Therapeutics’ employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
Some companies that are related to Sarepta Therapeutics include Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), CureVac (CVAC), UCB (UCBJF), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN) and Teva Pharmaceutical Industries (TEVA).
View all of SRPT’s competitors.
Based on aggregate information from Reportlab watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and The Walt Disney (DIS).
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol “SRPT.”
1 | | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
Sarepta Therapeutics’ stock is owned by many different institutional and retail investors. Top institutional investors include First Trust Advisors LP (0.68%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), Swiss National Bank (0.36%), California Public Employees Retirement System (0.23%), Candriam Luxembourg S.C.A. (0.21%) and C WorldWide Group Holding A S (0.15%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme.
View institutional ownership trends for Sarepta Therapeutics.
SRPT stock was sold by a variety of institutional investors in the last quarter, including Los Angeles Capital Management LLC, First Trust Advisors LP, C WorldWide Group Holding A S, Candriam Luxembourg S.C.A., Swiss National Bank, State of Wisconsin Investment Board, Pinnacle Associates Ltd., and Strs Ohio. Company insiders that have sold Sarepta Therapeutics company stock in the last year include David T Howton, Hans Lennart Rudolf Wigzell, Joseph Bratica, and Richard Barry.
View insider buying and selling activity for Sarepta Therapeutics or view top insider-selling stocks.
SRPT stock was purchased by a variety of institutional investors in the last quarter, including TCW Group Inc., Lehman & Derafelo Financial Resources LLC, CWM LLC, DNB Asset Management AS, Zurcher Kantonalbank Zurich Cantonalbank, California Public Employees Retirement System, WBI Investments, and Nia Impact Advisors LLC. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, M Kathleen Behrens, Michael W Bonney, and Richard Barry.
View insider buying and selling activity for Sarepta Therapeutics or or view top insider-buying stocks.
Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Interactive Brokers Review, eToro Review, Przegląd DEGiro, AvaTrade Review, IG Markets Review, IC Markets Review, CMC Markets Review, Admiral Markets Review i wiele innych. Proszę przeczytać jedną z recenzji, aby dowiedzieć się wszystkiego o brokerze i zacząć kupować akcje już teraz.
One share of SRPT stock can currently be purchased for approximately $95.73.
Sarepta Therapeutics has a market capitalization of $7.55 billion and generates $380.83 million in revenue each year. The biotechnology company earns $-715,080,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis.
Na Reportlab.org chcemy się upewnić, że mają Państwo wszystkie najbardziej istotne informacje na temat kupno akcji. Przynosimy Państwu najlepsze przewodniki po giełdzie z osobistymi opiniami, informacjami uzupełniającymi, opiniami o platformach, how to's i więcej. Chcą Państwo uzyskać inne informacje? Proszę zajrzeć na stronę Akcje OTC, Akcje NASDAQ, Akcje na NYSE, Akcje LON, Akcje FRA, Akcje ETR, Zapasy EPA, Akcje TSX lub Akcje Amex. Szukam bardziej szczegółowych informacji, takich jak 5g zapasy, akcje biotechnologiczne, akcje złota i inne informacje z naszego Reportlab.
How can you buy Sarepta Therapeutics stock on the internet?
You can easily buy Sarepta Therapeutics stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Inną opcją jest skorzystanie z usług regulowanego brokera, jak np. IC Markets lub Interactive Brokers. You can an account with these brokers and start buying or trading NASDAQ:SRPT stocks in a safe and complete environment to trade in.
Where to buy Sarepta Therapeutics stock?
You will first want to find a licensed broker that supports NASDAQ:SRPT stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:SRPT stocks in a safe and complete environment.
Is NASDAQ:SRPT stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:SRPT stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Sarepta Therapeutics stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:SRPT is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Sarepta Therapeutics stock.
How do you trade Sarepta Therapeutics stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Sarepta Therapeutics stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:SRPT stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Sarepta Therapeutics stock?
To sell your NASDAQ:SRPT stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Sarepta Therapeutics stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:SRPT stock.
Stephen wie wiele o produktach finansowych, a w szczególności pasjonuje się rynkami giełdowymi i ich uczestnikami. Mamy nadzieję, że przedstawione informacje będą dla Państwa pomocne. Coś nie jest całkiem jasne? Proszę zostawić swoje pytania lub komentarze na dole strony.
| Nasz wynik ★★★★★ | |
| Nasz wynik ★★★★★ | |
| Nasz wynik ★★★★★ |
Newsletter
Najnowsze wiadomości
| |
Nasz wynik |
0% prowizja |
Paryska Giełda Papierów Wartościowych (EPA)
Wszystkie akcje EPA Więcej informacji Akcje EPA Czym jest Paryska Giełda Papierów Wartościowych (EPA)? Teraz
Dane o akcjach i kryptowalutach w czasie rzeczywistym
Powiadomienia, Porady & Nowości
Best Stocks & Crypto Guides
Recenzje brokerów i giełd online
Reportlab Finance jest stroną czysto informacyjną i w żadnym wypadku nie oznacza doradztwa inwestycyjnego. Wszystkie inwestycje niosą ze sobą ryzyko i mogą Państwo stracić wszystkie swoje inwestycje. Proszę nie inwestować pieniędzy, na których utratę nie mogą sobie Państwo pozwolić.
Reportlab Finance
38 Holburn Lane
Heckfield Green
IP21 0UB
Zjednoczone Królestwo
Copyright © 2022 Reportlab.Finance | Wszystkie prawa zastrzeżone.
